---
document_datetime: 2025-12-02 06:08:17
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/medicines/human/EPAR/mylotarg.html
document_name: mylotarg.html
version: success
processing_time: 0.1122059
conversion_datetime: 2025-12-27 14:25:36.446467
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
# Mylotarg

[RSS](/en/individual-human-medicine.xml/66273)

##### Authorised

This medicine is authorised for use in the European Union

gemtuzumab ozogamicin Medicine Human Authorised

Page contents

## Page contents

- [Overview](#overview)
- [Product information](#product-info)
- [Product details](#product-details)
- [Authorisation details](#authorisation-details)
- [Assessment history](#assessment-history)
- [News on Mylotarg](#news-on)
- [More information on Mylotarg](#related-medicines)
- [Topics](#topics)

- Application under evaluation
- CHMP opinion
- European Commission decision

## Overview

Mylotarg is a medicine used to treat a blood cancer called acute myeloid leukaemia (AML) in patients aged 15 years and above who are newly diagnosed and have not tried other treatments.

It is used in combination with daunorubicin and cytarabine (other cancer medicines).

Mylotarg is used in patients with a protein called CD33 on their cancer cells (which is the case in most patients with AML). It is not used for a type of AML called acute promyelocytic leukaemia (APL).

AML is rare, and Mylotarg was designated an 'orphan medicine' (a medicine used in rare diseases) on 18 October 2000.

Mylotarg contains the active substance gemtuzumab ozogamicin.

Expand section

Collapse section

## How is Mylotarg used?

Mylotarg is given as an infusion into a vein lasting 2 hours. The patient usually receives 3 infusions within one week. The patient will also be given two other medicines: daunorubicin and cytarabine.

If the cancer responds to initial treatment, the patient may receive further 'consolidation' treatment to keep the cancer from coming back.

Mylotarg infusions must be given in a place (such as a hospital) where the patient can be resuscitated if there are severe reactions. The patient is also given medicines to help prevent reactions such as reddening of the skin, chills and fever.

For more information about using Mylotarg, see the package leaflet or contact your doctor or pharmacist. Mylotarg can only be obtained with a prescription.

## How does Mylotarg work?

The active substance in Mylotarg, gemtuzumab ozogamicin, consists of two parts: a cytotoxic (cell-killing) substance and a monoclonal antibody (a type of protein).

The monoclonal antibody part (gemtuzumab) has been designed to attach to CD33. When the antibody attaches to CD33 on leukaemia cells, the cells absorb the antibody, as well as the cytotoxic substance that it is attached to. Inside the cells, the cytotoxic substance, which is called calicheamicin, is released. The calicheamicin then breaks up the cells' DNA, eventually killing the cells.

## What benefits of Mylotarg have been shown in studies?

A main study in 271 patients with AML has shown that adding Mylotarg to daunorubicin and cytarabine can prolong the time patients live without their cancer coming back by around 8 months.

In patients receiving Mylotarg in combination with daunorubicin and cytarabine, it took an average of 17.3 months until the treatment failed, the cancer came back or the patient died, compared with 9.5 months in patients receiving a combination of only daunorubicin and cytarabine.

## What are the risks associated with Mylotarg?

The most common side effects with Mylotarg when given in combination with daunorubicin and cytarabine (which may affect more than 3 in 10 people) are bleeding and severe infections. These side effects can be serious in more than 1 in 10 people. Other serious side effects with the combination therapy are liver disease, including veno-occlusive disease (a liver injury), and tumour lysis syndrome (a complication due to the breakdown of cancer cells).

For the full list of side effects and restrictions with Mylotarg, see the package leaflet.

## Why is Mylotarg authorised in the EU?

Mylotarg, given in combination with daunorubicin and cytarabine, has been shown to prolong the time patients lived before the cancer came back by up to 8 months. Although some side effects with Mylotarg can be serious, they were considered acceptable in light of the severity of the patients' condition.

The European Medicines Agency decided that Mylotarg's benefits are greater than its risks and it can be authorised for use in the EU.

## What measures are being taken to ensure the safe and effective use of Mylotarg?

Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Mylotarg have been included in the summary of product characteristics and the package leaflet.

As for all medicines, data on the use of Mylotarg are continuously monitored. Side effects reported with Mylotarg are carefully evaluated and any necessary action taken to protect patients.

## Other information about Mylotarg

Mylotarg received a marketing authorisation valid throughout the EU on 19 April 2018.

Mylotarg : EPAR - Summary for the public

Reference Number: EMA/246931/2018

English (EN) (75.51 KB - PDF)

**First published:** 04/05/2018

**Last updated:** 04/05/2018

[View](/en/documents/overview/mylotarg-epar-summary-public_en.pdf)

[Other languages (22)](#file-language-dropdown-48)

български (BG) (102.47 KB - PDF)

**First published:**

04/05/2018

**Last updated:**

04/05/2018

[View](/bg/documents/overview/mylotarg-epar-summary-public_bg.pdf)

español (ES) (75.42 KB - PDF)

**First published:**

04/05/2018

**Last updated:**

04/05/2018

[View](/es/documents/overview/mylotarg-epar-summary-public_es.pdf)

čeština (CS) (99.89 KB - PDF)

**First published:**

04/05/2018

**Last updated:**

04/05/2018

[View](/cs/documents/overview/mylotarg-epar-summary-public_cs.pdf)

dansk (DA) (73.58 KB - PDF)

**First published:**

04/05/2018

**Last updated:**

04/05/2018

[View](/da/documents/overview/mylotarg-epar-summary-public_da.pdf)

Deutsch (DE) (76.44 KB - PDF)

**First published:**

04/05/2018

**Last updated:**

04/05/2018

[View](/de/documents/overview/mylotarg-epar-summary-public_de.pdf)

eesti keel (ET) (73.55 KB - PDF)

**First published:**

04/05/2018

**Last updated:**

04/05/2018

[View](/et/documents/overview/mylotarg-epar-summary-public_et.pdf)

ελληνικά (EL) (108.78 KB - PDF)

**First published:**

04/05/2018

**Last updated:**

04/05/2018

[View](/el/documents/overview/mylotarg-epar-summary-public_el.pdf)

français (FR) (76.35 KB - PDF)

**First published:**

04/05/2018

**Last updated:**

04/05/2018

[View](/fr/documents/overview/mylotarg-epar-summary-public_fr.pdf)

hrvatski (HR) (94.96 KB - PDF)

**First published:**

04/05/2018

**Last updated:**

04/05/2018

[View](/hr/documents/overview/mylotarg-epar-summary-public_hr.pdf)

italiano (IT) (75.07 KB - PDF)

**First published:**

04/05/2018

**Last updated:**

04/05/2018

[View](/it/documents/overview/mylotarg-epar-summary-public_it.pdf)

latviešu valoda (LV) (104.01 KB - PDF)

**First published:**

04/05/2018

**Last updated:**

04/05/2018

[View](/lv/documents/overview/mylotarg-epar-summary-public_lv.pdf)

lietuvių kalba (LT) (98.26 KB - PDF)

**First published:**

04/05/2018

**Last updated:**

04/05/2018

[View](/lt/documents/overview/mylotarg-epar-summary-public_lt.pdf)

magyar (HU) (95.1 KB - PDF)

**First published:**

04/05/2018

**Last updated:**

04/05/2018

[View](/hu/documents/overview/mylotarg-epar-summary-public_hu.pdf)

Malti (MT) (99.43 KB - PDF)

**First published:**

04/05/2018

**Last updated:**

04/05/2018

[View](/mt/documents/overview/mylotarg-epar-summary-public_mt.pdf)

Nederlands (NL) (75.07 KB - PDF)

**First published:**

04/05/2018

**Last updated:**

04/05/2018

[View](/nl/documents/overview/mylotarg-epar-summary-public_nl.pdf)

polski (PL) (99.31 KB - PDF)

**First published:**

04/05/2018

**Last updated:**

04/05/2018

[View](/pl/documents/overview/mylotarg-epar-summary-public_pl.pdf)

português (PT) (75.7 KB - PDF)

**First published:**

04/05/2018

**Last updated:**

04/05/2018

[View](/pt/documents/overview/mylotarg-epar-summary-public_pt.pdf)

română (RO) (104.3 KB - PDF)

**First published:**

04/05/2018

**Last updated:**

04/05/2018

[View](/ro/documents/overview/mylotarg-epar-summary-public_ro.pdf)

slovenčina (SK) (99.13 KB - PDF)

**First published:**

04/05/2018

**Last updated:**

04/05/2018

[View](/sk/documents/overview/mylotarg-epar-summary-public_sk.pdf)

slovenščina (SL) (93.91 KB - PDF)

**First published:**

04/05/2018

**Last updated:**

04/05/2018

[View](/sl/documents/overview/mylotarg-epar-summary-public_sl.pdf)

Suomi (FI) (74.75 KB - PDF)

**First published:**

04/05/2018

**Last updated:**

04/05/2018

[View](/fi/documents/overview/mylotarg-epar-summary-public_fi.pdf)

svenska (SV) (73.99 KB - PDF)

**First published:**

04/05/2018

**Last updated:**

04/05/2018

[View](/sv/documents/overview/mylotarg-epar-summary-public_sv.pdf)

Mylotarg : EPAR - Risk-management-plan summary

English (EN) (1.76 MB - PDF)

**First published:** 21/07/2022

[View](/en/documents/rmp-summary/mylotarg-epar-risk-management-plan-summary_en.pdf)

## Product information

Mylotarg : EPAR - Product Information

English (EN) (554.02 KB - PDF)

**First published:** 04/05/2018

**Last updated:** 17/09/2025

[View](/en/documents/product-information/mylotarg-epar-product-information_en.pdf)

[Other languages (24)](#file-language-dropdown-111)

български (BG) (360.77 KB - PDF)

**First published:**

04/05/2018

**Last updated:**

17/09/2025

[View](/bg/documents/product-information/mylotarg-epar-product-information_bg.pdf)

español (ES) (343.7 KB - PDF)

**First published:**

04/05/2018

**Last updated:**

17/09/2025

[View](/es/documents/product-information/mylotarg-epar-product-information_es.pdf)

čeština (CS) (363.69 KB - PDF)

**First published:**

04/05/2018

**Last updated:**

17/09/2025

[View](/cs/documents/product-information/mylotarg-epar-product-information_cs.pdf)

dansk (DA) (337.78 KB - PDF)

**First published:**

04/05/2018

**Last updated:**

17/09/2025

[View](/da/documents/product-information/mylotarg-epar-product-information_da.pdf)

Deutsch (DE) (367.54 KB - PDF)

**First published:**

04/05/2018

**Last updated:**

17/09/2025

[View](/de/documents/product-information/mylotarg-epar-product-information_de.pdf)

eesti keel (ET) (352.2 KB - PDF)

**First published:**

04/05/2018

**Last updated:**

17/09/2025

[View](/et/documents/product-information/mylotarg-epar-product-information_et.pdf)

ελληνικά (EL) (376.69 KB - PDF)

**First published:**

04/05/2018

**Last updated:**

17/09/2025

[View](/el/documents/product-information/mylotarg-epar-product-information_el.pdf)

français (FR) (359.82 KB - PDF)

**First published:**

04/05/2018

**Last updated:**

17/09/2025

[View](/fr/documents/product-information/mylotarg-epar-product-information_fr.pdf)

hrvatski (HR) (364.73 KB - PDF)

**First published:**

04/05/2018

**Last updated:**

17/09/2025

[View](/hr/documents/product-information/mylotarg-epar-product-information_hr.pdf)

íslenska (IS) (358.31 KB - PDF)

**First published:**

04/05/2018

**Last updated:**

17/09/2025

[View](/is/documents/product-information/mylotarg-epar-product-information_is.pdf)

italiano (IT) (334.49 KB - PDF)

**First published:**

04/05/2018

**Last updated:**

17/09/2025

[View](/it/documents/product-information/mylotarg-epar-product-information_it.pdf)

latviešu valoda (LV) (363.9 KB - PDF)

**First published:**

04/05/2018

**Last updated:**

17/09/2025

[View](/lv/documents/product-information/mylotarg-epar-product-information_lv.pdf)

lietuvių kalba (LT) (355.65 KB - PDF)

**First published:**

04/05/2018

**Last updated:**

17/09/2025

[View](/lt/documents/product-information/mylotarg-epar-product-information_lt.pdf)

magyar (HU) (371.33 KB - PDF)

**First published:**

04/05/2018

**Last updated:**

17/09/2025

[View](/hu/documents/product-information/mylotarg-epar-product-information_hu.pdf)

Malti (MT) (394.37 KB - PDF)

**First published:**

04/05/2018

**Last updated:**

17/09/2025

[View](/mt/documents/product-information/mylotarg-epar-product-information_mt.pdf)

Nederlands (NL) (354.45 KB - PDF)

**First published:**

04/05/2018

**Last updated:**

17/09/2025

[View](/nl/documents/product-information/mylotarg-epar-product-information_nl.pdf)

norsk (NO) (358.45 KB - PDF)

**First published:**

04/05/2018

**Last updated:**

17/09/2025

[View](/no/documents/product-information/mylotarg-epar-product-information_no.pdf)

polski (PL) (358.72 KB - PDF)

**First published:**

04/05/2018

**Last updated:**

17/09/2025

[View](/pl/documents/product-information/mylotarg-epar-product-information_pl.pdf)

português (PT) (331.73 KB - PDF)

**First published:**

04/05/2018

**Last updated:**

17/09/2025

[View](/pt/documents/product-information/mylotarg-epar-product-information_pt.pdf)

română (RO) (367.1 KB - PDF)

**First published:**

04/05/2018

**Last updated:**

17/09/2025

[View](/ro/documents/product-information/mylotarg-epar-product-information_ro.pdf)

slovenčina (SK) (353.71 KB - PDF)

**First published:**

04/05/2018

**Last updated:**

17/09/2025

[View](/sk/documents/product-information/mylotarg-epar-product-information_sk.pdf)

slovenščina (SL) (352.72 KB - PDF)

**First published:**

04/05/2018

**Last updated:**

17/09/2025

[View](/sl/documents/product-information/mylotarg-epar-product-information_sl.pdf)

Suomi (FI) (362.61 KB - PDF)

**First published:**

04/05/2018

**Last updated:**

17/09/2025

[View](/fi/documents/product-information/mylotarg-epar-product-information_fi.pdf)

svenska (SV) (342.47 KB - PDF)

**First published:**

04/05/2018

**Last updated:**

17/09/2025

[View](/sv/documents/product-information/mylotarg-epar-product-information_sv.pdf)

**Latest procedure affecting product information:** VR/0000278463 11/09/2025

icon globe

<!-- image -->

This medicine's product information is available in all **official EU languages** . Select 'available languages' to access the language you need.

Product information documents contain:

- summary of product characteristics (annex I);
- manufacturing authorisation holder responsible for batch release (annex IIA);
- conditions of the marketing authorisation (annex IIB);
- labelling (annex IIIA);
- package leaflet (annex IIIB).

Mylotarg : EPAR - All Authorised presentations

English (EN) (89.79 KB - PDF)

**First published:** 04/05/2018

**Last updated:** 04/05/2018

[View](/en/documents/all-authorised-presentations/mylotarg-epar-all-authorised-presentations_en.pdf)

[Other languages (24)](#file-language-dropdown-590)

български (BG) (31.15 KB - PDF)

**First published:**

04/05/2018

**Last updated:**

04/05/2018

[View](/bg/documents/all-authorised-presentations/mylotarg-epar-all-authorised-presentations_bg.pdf)

español (ES) (28.49 KB - PDF)

**First published:**

04/05/2018

**Last updated:**

04/05/2018

[View](/es/documents/all-authorised-presentations/mylotarg-epar-all-authorised-presentations_es.pdf)

čeština (CS) (30.16 KB - PDF)

**First published:**

04/05/2018

**Last updated:**

04/05/2018

[View](/cs/documents/all-authorised-presentations/mylotarg-epar-all-authorised-presentations_cs.pdf)

dansk (DA) (30.3 KB - PDF)

**First published:**

04/05/2018

**Last updated:**

04/05/2018

[View](/da/documents/all-authorised-presentations/mylotarg-epar-all-authorised-presentations_da.pdf)

Deutsch (DE) (28.57 KB - PDF)

**First published:**

04/05/2018

**Last updated:**

04/05/2018

[View](/de/documents/all-authorised-presentations/mylotarg-epar-all-authorised-presentations_de.pdf)

eesti keel (ET) (28.44 KB - PDF)

**First published:**

04/05/2018

**Last updated:**

04/05/2018

[View](/et/documents/all-authorised-presentations/mylotarg-epar-all-authorised-presentations_et.pdf)

ελληνικά (EL) (30.83 KB - PDF)

**First published:**

04/05/2018

**Last updated:**

04/05/2018

[View](/el/documents/all-authorised-presentations/mylotarg-epar-all-authorised-presentations_el.pdf)

français (FR) (28.76 KB - PDF)

**First published:**

04/05/2018

**Last updated:**

04/05/2018

[View](/fr/documents/all-authorised-presentations/mylotarg-epar-all-authorised-presentations_fr.pdf)

hrvatski (HR) (28.64 KB - PDF)

**First published:**

04/05/2018

**Last updated:**

04/05/2018

[View](/hr/documents/all-authorised-presentations/mylotarg-epar-all-authorised-presentations_hr.pdf)

íslenska (IS) (29.64 KB - PDF)

**First published:**

04/05/2018

**Last updated:**

04/05/2018

[View](/is/documents/all-authorised-presentations/mylotarg-epar-all-authorised-presentations_is.pdf)

italiano (IT) (28.3 KB - PDF)

**First published:**

04/05/2018

**Last updated:**

04/05/2018

[View](/it/documents/all-authorised-presentations/mylotarg-epar-all-authorised-presentations_it.pdf)

latviešu valoda (LV) (29.89 KB - PDF)

**First published:**

04/05/2018

**Last updated:**

04/05/2018

[View](/lv/documents/all-authorised-presentations/mylotarg-epar-all-authorised-presentations_lv.pdf)

lietuvių kalba (LT) (29.14 KB - PDF)

**First published:**

04/05/2018

**Last updated:**

04/05/2018

[View](/lt/documents/all-authorised-presentations/mylotarg-epar-all-authorised-presentations_lt.pdf)

magyar (HU) (30.81 KB - PDF)

**First published:**

04/05/2018

**Last updated:**

04/05/2018

[View](/hu/documents/all-authorised-presentations/mylotarg-epar-all-authorised-presentations_hu.pdf)

Malti (MT) (29.6 KB - PDF)

**First published:**

04/05/2018

**Last updated:**

04/05/2018

[View](/mt/documents/all-authorised-presentations/mylotarg-epar-all-authorised-presentations_mt.pdf)

Nederlands (NL) (28.68 KB - PDF)

**First published:**

04/05/2018

**Last updated:**

04/05/2018

[View](/nl/documents/all-authorised-presentations/mylotarg-epar-all-authorised-presentations_nl.pdf)

norsk (NO) (30.24 KB - PDF)

**First published:**

04/05/2018

**Last updated:**

04/05/2018

[View](/no/documents/all-authorised-presentations/mylotarg-epar-all-authorised-presentations_no.pdf)

polski (PL) (30.21 KB - PDF)

**First published:**

04/05/2018

**Last updated:**

04/05/2018

[View](/pl/documents/all-authorised-presentations/mylotarg-epar-all-authorised-presentations_pl.pdf)

português (PT) (29.52 KB - PDF)

**First published:**

04/05/2018

**Last updated:**

04/05/2018

[View](/pt/documents/all-authorised-presentations/mylotarg-epar-all-authorised-presentations_pt.pdf)

română (RO) (29.28 KB - PDF)

**First published:**

04/05/2018

**Last updated:**

04/05/2018

[View](/ro/documents/all-authorised-presentations/mylotarg-epar-all-authorised-presentations_ro.pdf)

slovenčina (SK) (30.14 KB - PDF)

**First published:**

04/05/2018

**Last updated:**

04/05/2018

[View](/sk/documents/all-authorised-presentations/mylotarg-epar-all-authorised-presentations_sk.pdf)

slovenščina (SL) (29.03 KB - PDF)

**First published:**

04/05/2018

**Last updated:**

04/05/2018

[View](/sl/documents/all-authorised-presentations/mylotarg-epar-all-authorised-presentations_sl.pdf)

Suomi (FI) (28.05 KB - PDF)

**First published:**

04/05/2018

**Last updated:**

04/05/2018

[View](/fi/documents/all-authorised-presentations/mylotarg-epar-all-authorised-presentations_fi.pdf)

svenska (SV) (28.78 KB - PDF)

**First published:**

04/05/2018

**Last updated:**

04/05/2018

[View](/sv/documents/all-authorised-presentations/mylotarg-epar-all-authorised-presentations_sv.pdf)

## Product details

Name of medicine Mylotarg Active substance gemtuzumab ozogamicin International non-proprietary name (INN) or common name gemtuzumab ozogamicin Therapeutic area (MeSH) Leukemia, Myeloid, Acute

### Pharmacotherapeutic group

Antineoplastic agents

### Therapeutic indication

Mylotarg is indicated for combination therapy with daunorubicin (DNR) and cytarabine (AraC) for the treatment of patients age 15 years and above with previously untreated, de novo CD33-positive acute myeloid leukaemia (AML), except acute promyelocytic leukaemia (APL).

## Authorisation details

EMA product number EMEA/H/C/004204

Orphan

This medicine was designated an orphan medicine. This means that it was developed for use against a rare, life-threatening or chronically debilitating condition or, for economic reasons, it would be unlikely to have been developed without incentives. For more information, see [Orphan designation](/node/69983) .

Marketing authorisation holder

Pfizer Europe MA EEIG

Boulevard de la Plaine 17

Opinion adopted 22/02/2018 Marketing authorisation issued 19/04/2018 Revision 13

## Assessment history

Expand section

Collapse section

## Changes since initial authorisation of medicine

Mylotarg : EPAR - Procedural steps taken and scientific information after authorisation

English (EN) (218.38 KB - PDF)

**First published:** 17/09/2025

[View](/en/documents/procedural-steps-after/mylotarg-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf)

Mylotarg : EPAR - Procedural steps taken and scientific information after authorisation (archive)

English (EN) (204.25 KB - PDF)

**First published:** 15/08/2018

**Last updated:** 17/09/2025

[View](/en/documents/procedural-steps-after/mylotarg-epar-procedural-steps-taken-scientific-information-after-authorisation-archive_en.pdf)

Mylotarg-H-C-4204-II-0007 : EPAR - Assessment report - Variation

Adopted

Reference Number: EMA/CHMP/393390/2019

English (EN) (178.77 KB - PDF)

**First published:** 25/10/2019

[View](/en/documents/variation-report/mylotarg-h-c-4204-ii-0007-epar-assessment-report-variation_en.pdf)

Mylotarg-H-C-4204-P46-003 : EPAR - Assessment report

Adopted

Reference Number: EMA/780336/2018

English (EN) (857.1 KB - PDF)

**First published:** 08/01/2019

[View](/en/documents/variation-report/mylotarg-h-c-4204-p46-003-epar-assessment-report_en.pdf)

## Initial marketing authorisation documents

Mylotarg : Orphan maintenance assessment report (initial authorisation)

Reference Number: EMA/164384/2018

English (EN) (276.25 KB - PDF)

**First published:** 04/05/2018

**Last updated:** 04/05/2018

[View](/en/documents/orphan-maintenance-report/mylotarg-orphan-maintenance-assessment-report-initial-authorisation_en.pdf)

Mylotarg : EPAR - Public assessment report

Reference Number: EMA/155284/2018

English (EN) (5.8 MB - PDF)

**First published:** 04/05/2018

**Last updated:** 04/05/2018

[View](/en/documents/assessment-report/mylotarg-epar-public-assessment-report_en.pdf)

CHMP summary of positive opinion for Mylotarg

Adopted

Reference Number: EMA/CHMP/85476/2018

English (EN) (69.1 KB - PDF)

**First published:** 23/02/2018

**Last updated:** 23/02/2018

[View](/en/documents/smop-initial/chmp-summary-positive-opinion-mylotarg_en.pdf)

#### News on Mylotarg

[Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 19-22 February 2018](/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-19-22-february-2018) 23/02/2018

#### More information on Mylotarg

- [EU/3/00/005 - orphan designation for treatment of acute myeloid leukaemia](/en/medicines/human/orphan-designations/eu-3-00-005)
- [EMEA-001733-PIP02-15-M03 - paediatric investigation plan](/en/medicines/human/paediatric-investigation-plans/emea-001733-pip02-15-m03)
- [GO-First: Real-world treatment patterns and effectiveness outcomes associated with gemtuzumab ozogamicin in first-line Acute Myeloid Leukaemia - post-authorisation study](https://catalogues.ema.europa.eu/study/50630)

#### Topics

- [Medicines](https://www.ema.europa.eu/en/search?f%5B0%5D=ema_search_topics%3A61)

**This page was last updated on** 17/09/2025

## Share this page

[Back to top](#main-content)